Login / Signup

De novo mutations in mitochondrial DNA of iPSCs produce immunogenic neoepitopes in mice and humans.

Tobias DeuseXiaomeng HuSean Agbor-EnohMartina KochMatthew H SpitzerAlessia GravinaMalik AlawiArgit MarishtaBjoern PetersZeynep Kosaloglu-YalcinYanqin YangRaja RajalingamDong WangBjoern NashanRainer KiefmannHermann ReichenspurnerHannah ValantineIrving L WeissmanSonja Schrepfer
Published in: Nature biotechnology (2019)
The utility of autologous induced pluripotent stem cell (iPSC) therapies for tissue regeneration depends on reliable production of immunologically silent functional iPSC derivatives. However, rejection of autologous iPSC-derived cells has been reported, although the mechanism underlying rejection is largely unknown. We hypothesized that de novo mutations in mitochondrial DNA (mtDNA), which has far less reliable repair mechanisms than chromosomal DNA, might produce neoantigens capable of eliciting immune recognition and rejection. Here we present evidence in mice and humans that nonsynonymous mtDNA mutations can arise and become enriched during reprogramming to the iPSC stage, long-term culture and differentiation into target cells. These mtDNA mutations encode neoantigens that provoke an immune response that is highly specific and dependent on the host major histocompatibility complex genotype. Our results reveal that autologous iPSCs and their derivatives are not inherently immunologically inert for autologous transplantation and suggest that iPSC-derived products should be screened for mtDNA mutations.
Keyphrases